1. A method of ameliorating the effect of a reduction in blood flow in peri-infarct brain tissue in ischemic disease or injury in a subject comprising administering to the subject an amount of a compound effective to inhibit the activity of a NCCa-ATP channel in a neuronal cell, a neuroglia cell, or a neural endothelial cell.
2. The method of claim 1, where said compound is a compound capable of effecting hypoglycemia in said subject, further comprising administration of glucose to said subject effective to at least partially ameliorate said hypoglycemic effects in said subject.
3. A method of inhibiting neuronal cell swelling in the brain of a subject, said method comprising administering to the subject a formulation comprising an effective amount of a compound that blocks the NCCa-ATP channel and a pharmaceutically acceptable carrier.
4. The method of claim 3, wherein said inhibiting neuronal cell swelling is further defined as preventing neuronal cell swelling.
5. The method of claim 3, where said formulation comprises a compound capable of effecting hypoglycemia in said subject, further comprising administration of glucose to said subject effective to at least partially ameliorate said hypoglycemic effects in said subject.
6. The method of claim 5, wherein said inhibiting neuronal cell swelling is further defined as preventing neuronal cell swelling.
7. The method of claim 1, wherein the amelioration of the effect of a reduction in blood flow comprises a reduction in cytotoxic edema, ionic edema andor vasogenic edema.
8. The method of claim 1, wherein the neuroglia cell is selected from the group consisting of astrocyte, ependymal cell, oligodentrocyte and microglia.
9. The method of claim 1, wherein the NCCa-ATP channel inhibitor is a type 1 sulfonylurea receptor antagonist selected from the group consisting of glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, glimepiride, estrogen, estradiol, estrone, estriol, genistein, diethystilbestrol, coumestrol, zearalenone, a compound that inhibits KATP channels.
10. A method of alleviating brain swelling in a subject, comprising administering to the subject a formulation comprising an effective amount of a compound that blocks the NCCa-ATP channel and a pharmaceutically acceptable carrier.
11. The method of claim 10, where said formulation is a formulation capable of effecting hypoglycemia in said subject, further comprising administration of glucose to said subject effective to at least partially ameliorate said hypoglycemic effects in said subject.
12. The method of claim 1, wherein compound effective to inhibit a NCCa-ATP channel is administered alimentarily, parenterally, topically, mucosally, or by injection into brain parenchema.
13. A pharmaceutical composition comprising a therapeutically effective amount of a compound that inhibits a NCCa-ATP channel or a pharmaceutically acceptable salt thereof, wherein said therapeutically effective amount is effective to ameliorate at least one effect of a reduction in blood flow in peri-infarct brain tissue in a subject suffering from ischemic disease in the brain or from brain injury.
14. The pharmaceutical composition of claim 13, wherein the compound that inhibits a NCCa-ATP channel is selected from the group consisting of glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, glimepiride, estrogen, estradiol, estrone, estriol, genistein, diethystilbestrol, coumestrol, and zearalenone.
15. The pharmaceutical composition of claim 13 wherein the composition further comprises glucose.
16. The pharmaceutical composition of claim 15, wherein the amount of said compound that inhibits a NCCa-ATP channel or pharmaceutically acceptable salt thereof is an amount that has a hypoglycemic effect in a subject to which the pharmaceutical composition is administered.
17. The pharmaceutical composition of claim 16, wherein the amount of said glucose is effective to reduce or eliminate a lowering of the blood glucose concentration by said compound or pharmaceutically acceptable salt in the subject to which the pharmaceutical composition is administered.
18. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition is neuroprotective.
19. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is neuroprotective.
20. A method of treating acute cerebral ischemia in a subject comprising administering to a subject an amount of a compound that inhibits a NCCa-ATP channel or a pharmaceutically acceptable salt thereof.
21. The method of claim 20, wherein the NCCa-ATP channel is expressed on neuronal cells, neuroglia cells, neural endothelial cells or a combination thereof.
22. The method of claim 20, wherein said NCCa-ATP channel inhibitor is selected from the group consisting of glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, glimepiride, estrogen, estradiol, estrone, estriol, genistein, diethystilbestrol, coumestrol, and zearalenone.
23. The method of claim 20, wherein the mode of administration of said NCCa-ATP channel inhibitor is selected from the group of modes of administration consisting of bolus injection, infusion, and bolus injection in combination with an infusion.
24. The method of claim 20, wherein said NCCa-ATP channel inhibitor is glibenclamide.
25. The method of claim 20, further comprising administering glucose to said subject.
26. The method of claim 25, wherein said NCCa-ATP channel inhibitor is selected from the group consisting of glibenclamide, tolbutamide, repaglinide, nateglinide, meglitinide, midaglizole, LY397364, LY389382, glyclazide, glimepiride, estrogen, estradiol, estrone, estriol, genistein, diethystilbestrol, coumestrol, and zearalenone.
27. The method of claim 26, wherein the mode of administration of said NCCa-ATP channel inhibitor is selected from the group of modes of administration consisting of bolus injection, infusion, and bolus injection in combination with an infusion.
28. The method of claim 20, wherein compound effective to inhibit a NCCa-ATP channel is administered alimentarily, parenterally, topically, mucosally, or by injection into brain parenchema.
29. A neuroprotective infusion kit comprising a compound that inhibits a NCCa-ATP channel in a neuronal cell, a neuroglia cell, a neural endothelial cell or a combination thereof and an intravenous (IV) infusion solution.
30. The neuroprotective infusion kit of claim 29, wherein said IV infusion solution is an IV infusion solution supplemented with glucose.
31. The neuroprotective infusion kit of claim 29 further comprising a neuroprotective bolus kit, wherein the neuroprotective bolus kit comprises a pre-loaded syringe of a compound that inhibits a NCCa-ATP channel in a neuronal cell, a neuroglia cell, a neural endothelial cell or a combination thereof within an IV solution.
32. The kit of claim 31, wherein said IV solution is an IV solution supplemented with glucose.
33. A method of preventing neural cell swelling in the brain of a subject, said method comprising administering to the subject a formulation comprising an effective amount of a compound that blocks the NCCa-ATP channel, glucose, and a pharmaceutically acceptable carrier.
34. A method of alleviating one or more effects of traumatic brain injury or cerebral ischemia stemming from neural cell swelling in a subject, comprising administering to the subject a formulation comprising an effective amount of a compound that blocks the NCCa-ATP channel, glucose, and a pharmaceutically acceptable carrier.
35. A method of alleviating one or more effects of traumatic brain injury or cerebral ischemia in a subject, comprising administering to the subject a formulation comprising an effective amount of a sulfonylurea compound and a pharmaceutically acceptable carrier.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A high-level language processor comprising:
at least one dispatcher;
at least one processing unit;
at least one addressing unit;
at least one program memory;
at least one data memory;
an instruction read from said at least one data memory;
said at least one dispatcher configured to read a category from said instruction obtained via said at least one program memory through an address calculated by said at least one addressing unit, wherein said at least one dispatcher is configured to pass a remaining portion of said instruction to said at least one processing unit if said at least one processing unit is not occupied and wherein said at least one processing unit is configured to execute said remaining portion of said instruction and place a result in said at least one data memory and wherein said dispatcher is configured to decrement a priority associated with a second instruction and not execute another instruction until a third instruction comprising a STOP bit is completed; and,
said at least one processing unit configured to power off if no instruction is executing in said at least one processing unit.
2. The high-level language processor of claim 1 wherein said instruction comprises data type information.
3. The high-level language processor of claim 1 wherein said at least one data memory comprises data type information.
4. The high-level language processor of claim 1 further comprising:
said dispatcher configured to ensure proper order of execution of said instruction.
5. The high-level language processor of claim 1 further comprising:
said dispatcher configured to dispatch instructions utilizing a as-soon-as-possible algorithm.
6. The high-level language processor of claim 1 further comprising:
a compiler that does not optimize an executable generated from a high-level programming language.
7. The high-level language processor of claim 1 further comprising:
said at least one dispatcher comprising at least one comparison unit wherein said at least one comparison unit is configured into a matrix and wherein said at least one comparison unit allows for faster processing units to be configured for more frequent use.
8. The high-level language processor of claim 1 further comprising:
said at least one dispatcher comprising at least one comparison unit wherein said at least one comparison unit is configured into a matrix and wherein said at least one comparison unit allows for lower power processing units to be configured for more frequent use.
9. The high-level language processor of claim 1 further comprising:
said at least one dispatcher comprising at least one comparison unit wherein said at least one comparison unit is configured into a matrix and wherein said at least one comparison unit allows for faster and lower power processing units to be configured for more frequent use depending on the state of the system battery.
10. The high-level language processor of claim 1 further comprising:
said at least one dispatcher comprising a first dispatcher and a second dispatcher configured to run in parallel.
11. A method of utilizing a high-level language processor comprising: creating at least one dispatcher;
coupling at least one processing unit to said at least one dispatcher;
coupling at least one addressing unit to said at least one dispatcher;
coupling at least one program memory to said at least one dispatcher and said at least one addressing unit;
coupling at least one data memory to said at least one processing unit;
calculating an address with said at least one addressing unit;
obtaining said instruction from said at least one program memory at said address;
decoding a category from said instruction via said at least one dispatcher;
determining if said at least one processing unit is not occupied;
passing a remaining portion of said instruction to said at least one processing unit;
executing said remaining portion of said instruction via said at least one processing unit;
generating a result in said at least one data memory;
decrementing a priority associated with a second instruction choosing to not execute another instruction until a third instruction comprising a STOP bit is completed; and,
powering said at least one processing unit off if no instruction is executing in said at least one processing unit.
12. The method of claim 11 further comprising:
obtaining data type information from said instruction.
13. The method of claim 11 further comprising:
obtaining data type information from said at least one data memory.
14. The method of claim 11 further comprising:
ensuring proper order of execution of said instruction.
15. The method of claim 11 further comprising:
dispatching instructions utilizing a as-soon-as-possible algorithm.
16. The method of claim 11 further comprising:
compiling a high-level programming language using a compiler without optimizing an executable generated from said high-level programming language.
17. The method of claim 11 further comprising:
configuring at least one comparison unit within said at least one dispatcher into a matrix wherein said at least one comparison unit allows for faster processing units to be configured for more frequent use.
18. The method of claim 11 further comprising:
configuring at least one comparison unit within said at least one dispatcher into a matrix wherein said at least one comparison unit allows for lower power processing units to be configured for more frequent use.
19. The method of claim 11 further comprising:
configuring at least one comparison unit within said at least one dispatcher into a matrix wherein said at least one comparison unit allows for faster and lower power processing units to be configured for more frequent use depending on the state of the system battery.
20. The method of claim 11 further comprising:
configuring said at least one dispatcher as a first dispatcher and a second dispatcher configured to run in parallel.